Biotech startups that raised Series B in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Qingdao Shi | Series B | $30.0M | 2026-11-09 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Celaid Therapeutics | Tokyo | Series B | $2.5M | 2026-10-05 |
| HITS | Seoul | Series B | $13.5M | 2026-09-28 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| Medefa | Zhuhai | Series B | $14.9M | 2026-09-02 |
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
| Hongxin Biology | Shenzhen | Series B | $14.0M | 2026-08-13 |
8 rows of the CSV in 5 of its 18 columns.
- The 457 biotech startups in Asia whose last round is Series B have raised $11.1B in total.
- 68 of them closed their most recent round in the last 12 months, $1.4B combined.
- The largest of those rounds is Syneron's $150.0M Series B, dated March 2026.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- Qiming Venture Partners is an investor in 7 of them, more than any other fund.
- Health care is the most common other sector, with 395 companies (86%).
- 15% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (41% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 457| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi, China | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Celaid Therapeutics | Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. | Biotech | Tokyo, Japan | Series B | $2.5M | 2026-10-05 | $17.1M | UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners | 1 to 10 | 2020 |
| HITS | HITS develops artificial intelligence software for drug discovery and pharmaceutical research. | Artificial intelligence | Seoul, South Korea | Series B | $13.5M | 2026-09-28 | $25.1M | Korea Investment Partners, Capstone Partners, Company K Partners +2 | 11 to 50 | 2020 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai, China | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou, China | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen, China | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing, China | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai, China | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| ThunderBio Innovation | ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. | Biotech | Jiaxing, China | Series B | $17.7M | 2026-06-15 | $34.6M | Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi | 11 to 50 | 2018 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou, China | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| Phytolon | Phytolon supplies natural food colors of high quality at low cost. | Biotech | Yoqne`am `illit, Israel | Series B | $23.6M | 2026-05-26 | $43.7M | MassChallenge, Trendlines Group, Millenium Food-Tech | 11 to 50 | 2018 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai, China | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| Restore Vision | Restore Vision develops a gene therapy to restore vision for patients with retinitis pigmentosa. | Biotech | Tokyo, Japan | Series B | $8.2M | 2026-04-15 | $26.7M | SMBC Venture Capital, ANRI, Spiral Capital +2 | 1 to 10 | 2016 |
| AnBogen Therapeutics | Anbogen Therapeutics is a clinical-stage biotech company developing science to help cancer patients. | Biotech | Nankang, Taiwan | Series B | $7.3M | 2026-04-13 | $19.8M | National Development Fund of Taiwan Government, China Development Industrial Bank (CDIB), Maxpro Ventures +1 | 11 to 50 | 2019 |
| CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian, China | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| Findcure | Findcure develops anti-cancer medications through drug discovery and development. | Biotech | Daxing, China | Series B | $14.5M | 2026-02-14 | $14.5M | Hecheng Capital, Renxi Fund, Yishang Huicheng Investments | 11 to 50 | 2019 |
| Transcend Vivoscope | Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. | Biotech | Haidian, China | Series B | $14.5M | 2026-02-10 | $14.5M | China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund | 11 to 50 | 2016 |
| Galux | Galux designs molecules to discover new drugs for incurable and rare diseases. | Artificial intelligence | Dogokdong, South Korea | Series B | $29.0M | 2026-02-09 | $36.3M | Dayli Partners | 11 to 50 | 2020 |
| Pandorum Technologies | Pandorum Technologies is a Bengaluru-based biotech startup. | Biotech | Bangalore, India | Series B | $18.0M | 2026-02-09 | $42.6M | 500 Global, IAN Group, 021 Capital +1 | 11 to 50 | 2011 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Shanghai, China | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
| Anlong Bio | Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. | Biotech | Beijing, China | Series B | $14.3M | 2026-01-07 | $14.3M | TaiKun Fund | 51 to 100 | 2019 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi, China | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| Rigen Biotech | Rigen Biotech provides molecular diagnosis of thyroid tumors. | Biotech | Minhang, China | Series B | $14.1M | 2025-11-28 | $29.8M | BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 | 101 to 250 | 2017 |
| CytoReason | CytoReason develops a cell-centered computational model of the human body to find patterns in biological data. | Artificial intelligence | Tel Aviv, Israel | Series B | $80.0M | 2024-07-17 | $100.0M | OurCrowd, Asymmetry Ventures, Pfizer | 101 to 250 | 2016 |
| LN Robotics | LN Robotics is a technology research firm that develops medical robots. | Biotech | Hanam, South Korea | Series B | $14.5M | 2024-07-09 | $21.3M | TIPS Program, Bluepoint, Mirae Asset Venture Investment +2 | 11 to 50 | 2019 |
| Alpha Biopharma | Alpha Biopharma is a clinical-stage biopharmaceutical company. | Biotech | Huangpu, China | Series B | $23.9M | 2024-06-22 | Qiming Venture Partners, TF Capital, LYZZ Capital | 51 to 100 | 2017 | |
| DOT Compliance | DOT Compliance provides a ready-to-use cloud-based quality and compliance management solution for regulated industries. | Biotech | Ness Ziona, Israel | Series B | $17.5M | 2024-04-15 | Vertex Ventures, TPY Capital, Israel Growth Partners | 101 to 250 | 2007 |
Table 1. Biotech startups that raised Series B in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 457.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi, China | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 3 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 4 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai, China | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 5 | CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian, China | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| 6 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai, China | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 7 | Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| 8 | Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi, China | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| 9 | Galux | Galux designs molecules to discover new drugs for incurable and rare diseases. | Artificial intelligence | Dogokdong, South Korea | Series B | $29.0M | 2026-02-09 | $36.3M | Dayli Partners | 11 to 50 | 2020 |
| 10 | Phytolon | Phytolon supplies natural food colors of high quality at low cost. | Biotech | Yoqne`am `illit, Israel | Series B | $23.6M | 2026-05-26 | $43.7M | MassChallenge, Trendlines Group, Millenium Food-Tech | 11 to 50 | 2018 |
Table 2. Biotech startups that raised Series B in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 7 | 2% | 2 | Novamab, CSR Biotech |
| 2 | CMB International Capital Corporation | Investment bank | Central, Hong Kong | 5 | 1% | 1 | HemaCell |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 5 | 1% | 2 | Alioth, D3 Bio |
| 4 | BioTrack Capital | Venture capital firm | Shanghai, China | 4 | 1% | 2 | Yuce Biotechnology, Rigen Biotech |
| 5 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 4 | 1% | 1 | HemaCell |
| 6 | Legend Capital | Venture capital firm | Beijing, China | 4 | 1% | 1 | Alioth |
| 7 | UTEC - The University of Tokyo Edge Capital Partners | Venture capital firm | Tokyo, Japan | 3 | 1% | 1 | Celaid Therapeutics |
| 8 | Huagai Capital | Private equity firm | Beijing, China | 3 | 1% | 2 | Bluesail Surgical, MindRank AI |
| 9 | Addor Capital | Venture capital firm | Nanjing, China | 3 | 1% | 1 | Layerwave Bio |
| 10 | IDG Capital | Private equity firm | Beijing, China | 3 | 1% | 1 | Layerwave Bio |
| 11 | GL Ventures LLC | Venture capital firm | Beijing, China | 3 | 1% | 1 | Etern |
| 12 | Gaorong Capital | Venture capital firm | Wangjing, China | 3 | 1% | 1 | Bivision |
| 13 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 3 | 1% | ||
| 14 | CICC Capital | Private equity firm | Beijing, China | 3 | 1% | ||
| 15 | Hillhouse Ventures | Venture capital firm | Singapore | 3 | 1% |
Table 3. Biotech startups that raised Series B in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 395 | 86% | $9.8B |
| Software | 32 | 7% | $837.5M |
| Artificial intelligence | 20 | 4% | $731.6M |
| Hardware | 17 | 4% | $120.2M |
| Education | 3 | 1% | $18.7M |
| Fintech | 2 | 0% | |
| Energy | 2 | 0% | $816.8M |
| Cybersecurity | 2 | 0% |
Table 4. Biotech startups that raised Series B in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 457 | 100% | $14.5M |
Table 5. Biotech startups that raised Series B in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 301 | 66% |
| South Korea | 75 | 16% |
| Israel | 26 | 6% |
| Japan | 23 | 5% |
| Singapore | 10 | 2% |
| India | 9 | 2% |
| Taiwan | 7 | 2% |
| Hong Kong | 6 | 1% |
Table 6. Biotech startups that raised Series B in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups that raised Series B in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 4 | 6% | $75.0M |
| October 2026 | 3 | 4% | $13.9M |
| September 2026 | 9 | 13% | $257.3M |
| August 2026 | 2 | 3% | $21.5M |
| July 2026 | 4 | 6% | $65.8M |
| June 2026 | 5 | 7% | $79.3M |
| May 2026 | 5 | 7% | $138.4M |
| April 2026 | 6 | 9% | $91.0M |
| March 2026 | 4 | 6% | $230.9M |
| February 2026 | 7 | 10% | $133.7M |
| January 2026 | 9 | 13% | $98.0M |
| December 2025 | 8 | 12% | $226.0M |
| November 2025 | 2 | 3% | $14.1M |
Table 8. Biotech startups that raised Series B in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 58 | 13% | $1.2B |
| 2025 | 51 | 11% | $839.3M |
| 2024 | 38 | 8% | $483.2M |
| 2023 | 61 | 13% | $981.3M |
| 2022 | 71 | 16% | $2.6B |
| 2021 | 55 | 12% | $2.4B |
Table 9. Biotech startups that raised Series B in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 0% |
| 2020 to 2022 | 69 | 15% |
| 2015 to 2019 | 221 | 48% |
| 2010 to 2014 | 92 | 20% |
| Before 2010 | 73 | 16% |
Table 10. Biotech startups that raised Series B in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 43 | 10% |
| 11 to 50 | 171 | 41% |
| 51 to 100 | 91 | 22% |
| 101 to 250 | 71 | 17% |
| 251 to 500 | 22 | 5% |
| 501 to 1,000 | 14 | 3% |
| 1,001 to 5,000 | 8 | 2% |
Table 11. Biotech startups that raised Series B in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Asia. On 16 November 2026 that is 457 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 457 rows: 94 have no round amount, 0 no city and 123 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Asia whose last round is Series B are on the list?
- 457, in the file dated 16 November 2026. 68 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 457 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.